• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

注射用生物制品的匹配安慰剂开发——实用指南

Matching placebo development for injectable biologics-a practical tutorial.

作者信息

Xin Lun, Zhang Zhe, Shah Kushan, Hashemi Venus, Li Xuanyue, Qin Grace, Ren Steven, Chen Wei, Li Yunsong

机构信息

BioDev Department, WuXi Biologics, 1 Cedarbrook Dr, Cranbury, NJ 08512, United States.

CMC Management, WuXi Biologics, 1 Cedarbrook Dr, Cranbury, NJ 08512, United States.

出版信息

Antib Ther. 2025 May 8;8(3):177-188. doi: 10.1093/abt/tbaf009. eCollection 2025 Jul.

DOI:10.1093/abt/tbaf009
PMID:40583907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12202036/
Abstract

BACKGROUND

In drug development, placebo-controlled trials are vital for assessing treatment efficacy. Developing a suitable placebo for injectable biologics presents unique challenges, particularly in matching the physical characteristics of the active drug without containing its active pharmaceutical ingredient.

METHODS

Our study developed a methodology for biologic placebo formulations, focusing on color and viscosity matching, in relevant chemical matrixes. A custom color deconvolution algorithm was used for precise color-matching, and sodium carboxymethyl cellulose (Na-CMC) was employed to adjust viscosity in different buffer systems. The interactions between buffers, color agents, and excipients were investigated to ensure consistency in physical properties. Stability testing was conducted under freeze/thaw and thermal stress conditions.

RESULTS

The color-matching algorithm successfully achieved visually indistinguishable results from the active drug, measured by an empirical parameter for color differences (ΔE values). Na-CMC was effective in matching the viscosity of biologic formulations, maintaining the desired physical appearance. Significant interactions between color agents and buffer systems influenced viscosity and osmolality. Stability tests confirmed that the placebo formulations retained their color, pH, and osmolality, with only minor viscosity changes after stress testing.

CONCLUSIONS

Our study presents a systematic approach to biologic placebo development, providing a reliable framework for matching the color and viscosity of biologics. The methods and findings support the use of tailored excipients and color-matching algorithms to ensure clinical blinding in trials, enhancing the rigor of drug efficacy assessments and contributing to future placebo design in biologic drug development.

摘要

背景

在药物研发中,安慰剂对照试验对于评估治疗效果至关重要。开发适用于注射用生物制品的安慰剂面临独特挑战,尤其是要在不包含活性药物成分的情况下匹配活性药物的物理特性。

方法

我们的研究开发了一种用于生物制品安慰剂配方的方法,重点在于在相关化学基质中进行颜色和粘度匹配。使用定制的颜色反卷积算法进行精确的颜色匹配,并采用羧甲基纤维素钠(Na-CMC)在不同缓冲系统中调节粘度。研究了缓冲液、色素和辅料之间的相互作用,以确保物理性质的一致性。在冻融和热应激条件下进行稳定性测试。

结果

通过颜色差异的经验参数(ΔE值)测量,颜色匹配算法成功实现了与活性药物在视觉上无法区分的结果。Na-CMC有效地匹配了生物制品配方的粘度,保持了所需的物理外观。色素与缓冲系统之间的显著相互作用影响了粘度和渗透压。稳定性测试证实,安慰剂配方保持了其颜色、pH值和渗透压,应激测试后粘度仅有轻微变化。

结论

我们的研究提出了一种系统的生物制品安慰剂开发方法,为匹配生物制品的颜色和粘度提供了可靠的框架。这些方法和研究结果支持使用定制的辅料和颜色匹配算法,以确保试验中的临床盲法,提高药物疗效评估的严谨性,并为生物药物研发中的未来安慰剂设计做出贡献。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/6c581e3a8cbb/tbaf009f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/84c6e242cadf/tbaf009f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/d94c802021e2/tbaf009f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/dc414cf87aec/tbaf009f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/44f4fa29cec2/tbaf009f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/87f1970538d1/tbaf009f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/6c581e3a8cbb/tbaf009f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/84c6e242cadf/tbaf009f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/d94c802021e2/tbaf009f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/dc414cf87aec/tbaf009f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/44f4fa29cec2/tbaf009f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/87f1970538d1/tbaf009f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df5/12202036/6c581e3a8cbb/tbaf009f6.jpg

相似文献

1
Matching placebo development for injectable biologics-a practical tutorial.注射用生物制品的匹配安慰剂开发——实用指南
Antib Ther. 2025 May 8;8(3):177-188. doi: 10.1093/abt/tbaf009. eCollection 2025 Jul.
2
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
6
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.生物制剂或托法替布用于初治类风湿关节炎患者:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 May 8;5(5):CD012657. doi: 10.1002/14651858.CD012657.
7
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.生物制剂或托法替布用于生物制剂治疗类风湿关节炎失败的患者:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD012591. doi: 10.1002/14651858.CD012591.
8
Pharmacological treatment of children with gastro-oesophageal reflux.胃食管反流患儿的药物治疗
Cochrane Database Syst Rev. 2014 Nov 24;2014(11):CD008550. doi: 10.1002/14651858.CD008550.pub2.
9
TNF-alpha inhibitors for ankylosing spondylitis.用于强直性脊柱炎的肿瘤坏死因子-α抑制剂
Cochrane Database Syst Rev. 2015 Apr 18;2015(4):CD005468. doi: 10.1002/14651858.CD005468.pub2.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块型银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5.

本文引用的文献

1
Developments in the Use of Indocyanine Green (ICG) Fluorescence in Colorectal Surgery.吲哚菁绿(ICG)荧光在结直肠手术中的应用进展
J Clin Med. 2024 Jul 9;13(14):4003. doi: 10.3390/jcm13144003.
2
Roadmap for Drug Product Development and Manufacturing of Biologics.生物制品的药物产品开发和制造路线图。
J Pharm Sci. 2024 Feb;113(2):314-331. doi: 10.1016/j.xphs.2023.11.004. Epub 2023 Nov 8.
3
Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors.重新思考安慰剂:在罕见肿瘤临床试验中采用合成对照臂。
Nat Med. 2023 Nov;29(11):2689-2692. doi: 10.1038/s41591-023-02578-z.
4
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations.美国批准的商业化高浓度抗体药物产品的系统评价:制剂组成、剂型设计和初级包装考虑因素。
MAbs. 2023 Jan-Dec;15(1):2205540. doi: 10.1080/19420862.2023.2205540.
5
Poly Ethylene Glycol (PEG)-Based Hydrogels for Drug Delivery in Cancer Therapy: A Comprehensive Review.聚乙二醇(PEG)基水凝胶在癌症治疗中的药物传递:全面综述。
Adv Healthc Mater. 2023 Jul;12(18):e2300105. doi: 10.1002/adhm.202300105. Epub 2023 May 1.
6
Rheological Properties of Sodium Carboxymethylcellulose Solutions in Dihydroxy Alcohol/Water Mixtures.羧甲基纤维素钠溶液在二元醇/水混合物中的流变性质
Materials (Basel). 2023 Jan 2;16(1):418. doi: 10.3390/ma16010418.
7
Developing Lyophilized Formulations for Protein Biopharmaceuticals Containing Salt that Produce Placebos of Corresponding Appearance.开发含有盐的蛋白质生物制药的冻干制剂,使其产生具有相应外观的安慰剂。
J Pharm Sci. 2022 Oct;111(10):2930-2937. doi: 10.1016/j.xphs.2022.06.020. Epub 2022 Jun 28.
8
The Different Colors of mAbs in Solution.溶液中单克隆抗体的不同颜色。
Antibodies (Basel). 2021 May 24;10(2):21. doi: 10.3390/antib10020021.
9
Natural unblinding of BCG vaccination trials.卡介苗接种试验的自然揭盲。
Vaccine. 2021 Apr 8;39(15):2017-2019. doi: 10.1016/j.vaccine.2021.03.039. Epub 2021 Mar 18.
10
A meta-research study revealed several challenges in obtaining placebos for investigator-initiated drug trials.一项元研究揭示了在进行研究者发起的药物试验中获得安慰剂时所面临的若干挑战。
J Clin Epidemiol. 2021 Mar;131:70-78. doi: 10.1016/j.jclinepi.2020.11.007. Epub 2020 Nov 24.